Home › Kidney Cancer (Renal Cell Carcinoma) › New York › New York City
Kidney Cancer (Renal Cell Carcinoma) clinical trials in New York City, NY
27 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RecruitingPhase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 NYC Site, New York
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
RecruitingPhase 1/2
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- NYU Langone Medical Center, New York
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- and 1 more
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RecruitingPhase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RecruitingPhase 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Manhattan Eye Ear and Throat Hospital, New York
- and 2 more
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecruitingPhase 1
- New York Cancer & Blood Specialists, New York
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RecruitingPhase 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- and 1 more
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RecruitingPhase 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Decision Aid (DA) for Renal Patients
Recruiting
- NYU Langone Health, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- NYU Langone Health, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Kidney Cancer (Renal Cell Carcinoma) trials in other cities
- Houston, TX35 studies
- Dallas, TX23 studies
- Nashville, TN23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Pittsburgh, PA15 studies
- Philadelphia, PA15 studies
- Queens, NY15 studies
- Cleveland, OH14 studies
- Jacksonville, FL14 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.